NEWS
Mar 11, 2026

SSRP Institute Announces Troscriptions as New Trusted Partner 

PARTNER ANNOUNCEMENT

WILLOUGHBY, Ohio, [Mar 11, 2026] — The SSRP Institute today announced the addition of Troscriptions as its newest Trusted Partner, following nomination by SSRP Fellow Dr. Elizabeth Yurth and upon completion of the organization’s internal clinical review and vetting process.

Troscriptions offers physician-formulated, pharmaceutical grade, precision-dosed health optimization formulations delivered through a buccal troche. This new partnership reflects SSRP’s ongoing commitment to connecting providers with companies aligned with its education-first mission and standards of scientific integrity within cellular medicine.

“This partnership makes sense because both organizations are laser-focused on helping clinicians practice with precision tools that make a real clinical impact,” said Dr. Scott Sherr, Chief Medical and Health Education Officer of Troscriptions. 

“Trusted Partners are selected because they bring real-world clinical value to our Community,” said Matthew Seeds, CEO at SSRP. “Our Members rely on us to maintain a network built on experience, thoughtful evaluation, and shared educational principles. We are excited to welcome Troscriptions into that ecosystem.”

The new Trusted Partner page for Troscriptions is now live on the SSRP website and serves as a centralized resource for Members and providers seeking additional information about the company, its mission, and its role in supporting clinical implementation.

Dr. Yurth, who nominated Troscriptions for consideration, shared that alignment in scientific philosophy and clinical usefulness made the partnership a natural fit for the SSRP Community. “Troscriptions stands out for their commitment to innovation, education, and supporting practitioners in the longevity and regenerative medicine space. Their platform and community have been invaluable for connecting like-minded clinicians and advancing the field. I’m proud to see them recognized by SSRP.” 

Through these partnerships, the SSRP aims to support providers by connecting them with vetted resources that complement training, protocol development, and implementation in practice.

For more information and to view the Troscriptions Partner Page, visit:
SSRP Troscriptions Partner Page


About the SSRP Institute

The SSRP Institute is an education-focused organization dedicated to advancing cellular medicine through evidence-based training, professional collaboration, and clinically relevant research. SSRP supports providers worldwide through certifications, events, and ongoing educational programming designed to improve patient outcomes and elevate the standard of care.

The Trusted Partner Network is invitation-only and based on real clinical application within the SSRP ecosystem. Companies are nominated by SSRP Members and undergo a vetting process designed to ensure alignment with SSRP’s educational standards and patient-centered approach. There are no pay-to-play arrangements, promotional contracts, or commission structures tied to inclusion in the network. 

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
BREAKING NEWS August 26, 2026 – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 24, 2026
Ep. 102 - Office Hours: PWC26 Virtual Summit Part 4
Preview Only
Office Hours PWC26 Virtual Summit Part 4 – Episode 102

Office Hours PWC26 Virtual Summit Part 4- Episode 102

  1. Compounded topical creams and GHK-Cu with microneedling (0:59)
  2. Detoxing before using copper (12:09)
  3. Patient onboarding process (12:54)
  4. Zinc and iron supplementation with GHK-Cu (23:41)
  5. Loss of taste after COVID (25:55)
  6. 3D CT scans for root canals (27:03)
  7. Oral bacteria swabs and GLP-1 effectiveness (28:00)
  8. Endocannabinoid system (29:07)
  9. GHK-Cu efficacy on wound beds (32:05)

Preview Only — Become a member for full access
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the molecule into the body, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 17, 2026
Ep. 101 - Office Hours: PWC26 Virtual Summit Part 3
Preview Only
Office Hours PWC26 Virtual Summit Part 3 – Episode 101

Office Hours PWC26 Virtual Summit Part 3 – Episode 101

1. Mitochondrial peptides (1:07)
2. MOTS-c cycle (3:50)
3. Injury site specific injection (9:25)
4. BPC-157 dosing (15:18)
5. Trusted labs (20:56)
6. What “redox” means (25:48)
7. Patient with cervical fusion, pain, and decreased range of motion (31:36)
8. Lipedema (37:03)
9. SS-31 and MOTS-c (37:52)
10. NanoVI device (44:49)
11. NAD (48:13)

Preview Only — Become a member for full access
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 10, 2026
Ep. 100 - Office Hours: PWC26 Virtual Summit Part 2
Preview Only
Office Hours PWC26 Virtual Summit Part 2 – Episode 100

Office Hours PWC26 Virtual Summit Part 2 – Episode 100

  1. Evaluating terrain of the patient (1:43)
  2. SS31 peptide in practice (8:50)
  3. Phenotyping the right patient for GLP-1 therapy (11:18)

 

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Aug 3, 2026
Ep. 099 - Office Hours: PWC26 Virtual Summit Part 1
Preview Only
Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

This special edition of Office Hours features questions submitted during the Peptide World Congress Virtual Summit on July 10 and 11. Dr. Seeds and Dr. Newman address:

  1. GLOW Stack, MOTS c, and Thyroid Function (0:50)
  2. Should the GLOW Stack Be Separated? (3:31)
  3. Peptides in Transplant Medicine (8:02)
  4. Biomarker Monitoring (13:21)
  5. Peptides in Acute and Long Term Stroke Recovery (17:37)
  6. Autoimmunity and the GI Tract (23:00)
  7. Cancer Concerns Related to Hormones and Angiogenesis (26:49)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Jul 27, 2026
Ep. 098 - Pentosan Polysulfate: Dosing, Safety, and Monitoring
Preview Only
Dissecting Protocols – Episode 098

Pentosan Polysulfate: Dosing, Safety, and Monitoring

Dr. Seeds examines the subcutaneous use of pentosan polysulfate, addressing concerns about injection site scarring and ocular safety. He discusses dosing, site rotation, cumulative exposure, retinal screening, and strategies for responsible, individualized treatment.(Question Link)

Preview Only — Become a member for full access
SSRP Institute Jul 24, 2026
PCAC Meeting Vote Summary
BREAKING NEWS JULY 24, 2026 – The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.Recommended FOR inclusion: (Yes-No)• BPC-157 (8–6)• KPV (8–6)• TB-500 (8–6)• MOTS-c (7–5)• Epitalon (7–4)• Semax (8–5)Recommended AGAINST inclusion: (Yes-No)• DSIP (6–7) What happens […]
READ NEWS

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.